Commerzbank Aktiengesellschaft’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-335,203	Closed	-$3.56K	–	1054
2016 Q2	$3.56K	Hold	335,203	–	–	0.02%	289
2016 Q1	$6.33M	Hold	335,203	–	–	0.05%	197
2015 Q4	$8.92M	Buy	335,203 +103	+0%	+$3.58K	0.07%	202
2015 Q3	$15.3M	Hold	335,100	–	–	0.11%	129
2015 Q2	$10.8M	Hold	335,100	–	–	0.06%	207
2015 Q1	$10.7M	Hold	335,100	–	–	0.06%	214
2014 Q4	$12.7M	Hold	335,100	–	–	0.08%	212
2014 Q3	$8.85M	Buy	335,100 +60,100	+22%	+$1.59M	0.04%	342
2014 Q2	$8.14M	Hold	275,000	–	–	0.04%	320
2014 Q1	$10.2M	Buy	275,000 +125,000	+83%	+$4.74M	0.04%	257
2013 Q4	$5.28M	Buy	150,000 +100,000	+200%	+$3.91M	0.03%	441
2013 Q3	$2.65M	Sell	50,000 -1,070	-2%	-$62.4K	0.01%	645
2013 Q2	$2.73M	Buy	+51,070	New	+$2.55M	0.01%	697

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Commerzbank Aktiengesellschaft's NAVB Position: Q3 2016 in Review

Commerzbank Aktiengesellschaft sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 335,203 shares — an estimated $3.56K sold.

Commerzbank Aktiengesellschaft first reported a position in NAVB in Q2 2013 and held it in 13 quarters. The position peaked at $15.3M in Q3 2015. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

Commerzbank Aktiengesellschaft reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
Commerzbank Aktiengesellschaft sold 335,203 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $3.56K.
Commerzbank Aktiengesellschaft first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 13 quarters.
Commerzbank Aktiengesellschaft's Navidea Biopharmaceuticals Inc. position peaked at $15.3M in Q3 2015.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q3 2016, filed 14 Nov 2016.